Current and future pharmacotherapy for alopecia areata

Norma Elizabeth Vázquez-Herrera, Antonella Tosti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Alopecia areata is a genetic and inflammatory disease that causes cosmetic and emotional distress. Current treatments are mainly focused in controlling inflammation, thus allowing hair regrowth, but not preventing relapse. Recent advances in the knowledge of the pathogenesis at the immunological and genetic level have provided new therapeutic approaches for this condition.Areas covered: Literature regarding available and future treatment options for alopecia areata was reviewed. We describe the mechanisms involved in its physiopathology and discuss extensively existing evidence for current treatment and status of new drugs, which act on specific target molecules such as Janus kinase (JAK) inhibitors, abatacept, IL-2, Hu-Mik-β-1, anti-IFN-γ, platelet-rich plasma (PRP), stem cell educator therapy, ezetimibe/simvastatin and tianeptine.Expert opinion: Advances in the knowledge of the physiopathology of alopecia areata have led to the discovery of new therapeutic targets for this illness. Treatments that have been successful in case reports or small studies are JAK inhibitors, abatacept, IL-2, anti-IFN-γ, PRP, ezetimibe/simvastatin and tianeptine. Even though these drugs have different mechanisms of action, their success will direct future research on drugs that act on a specific target. More clinical trials are needed to establish the safety and efficacy of these drugs, however, new treatment strategies are underway.

Original languageEnglish (US)
Pages (from-to)419-431
Number of pages13
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Alopecia Areata
tianeptine
Drug Therapy
Janus Kinases
Platelet-Rich Plasma
Simvastatin
Pharmaceutical Preparations
Therapeutics
Inborn Genetic Diseases
Expert Testimony
Cell- and Tissue-Based Therapy
Plasma Cells
Cosmetics
Hair
Stem Cells
Clinical Trials
Inflammation
Safety
Recurrence

Keywords

  • Abatacept
  • Alopecia totalis
  • Alopecia universalis
  • IFN-γ inhibitors
  • IL-2
  • Janus kinase inhibitors
  • Methotrexate
  • Platelet-rich plasma
  • Ruxolitinib
  • Tofacitinib

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Current and future pharmacotherapy for alopecia areata. / Vázquez-Herrera, Norma Elizabeth; Tosti, Antonella.

In: Expert Opinion on Orphan Drugs, Vol. 3, No. 4, 01.04.2015, p. 419-431.

Research output: Contribution to journalArticle

Vázquez-Herrera, Norma Elizabeth ; Tosti, Antonella. / Current and future pharmacotherapy for alopecia areata. In: Expert Opinion on Orphan Drugs. 2015 ; Vol. 3, No. 4. pp. 419-431.
@article{2305888d8d0d4e1eb7ca4504e2db8485,
title = "Current and future pharmacotherapy for alopecia areata",
abstract = "Introduction: Alopecia areata is a genetic and inflammatory disease that causes cosmetic and emotional distress. Current treatments are mainly focused in controlling inflammation, thus allowing hair regrowth, but not preventing relapse. Recent advances in the knowledge of the pathogenesis at the immunological and genetic level have provided new therapeutic approaches for this condition.Areas covered: Literature regarding available and future treatment options for alopecia areata was reviewed. We describe the mechanisms involved in its physiopathology and discuss extensively existing evidence for current treatment and status of new drugs, which act on specific target molecules such as Janus kinase (JAK) inhibitors, abatacept, IL-2, Hu-Mik-β-1, anti-IFN-γ, platelet-rich plasma (PRP), stem cell educator therapy, ezetimibe/simvastatin and tianeptine.Expert opinion: Advances in the knowledge of the physiopathology of alopecia areata have led to the discovery of new therapeutic targets for this illness. Treatments that have been successful in case reports or small studies are JAK inhibitors, abatacept, IL-2, anti-IFN-γ, PRP, ezetimibe/simvastatin and tianeptine. Even though these drugs have different mechanisms of action, their success will direct future research on drugs that act on a specific target. More clinical trials are needed to establish the safety and efficacy of these drugs, however, new treatment strategies are underway.",
keywords = "Abatacept, Alopecia totalis, Alopecia universalis, IFN-γ inhibitors, IL-2, Janus kinase inhibitors, Methotrexate, Platelet-rich plasma, Ruxolitinib, Tofacitinib",
author = "V{\'a}zquez-Herrera, {Norma Elizabeth} and Antonella Tosti",
year = "2015",
month = "4",
day = "1",
doi = "10.1517/21678707.2015.1021778",
language = "English (US)",
volume = "3",
pages = "419--431",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Current and future pharmacotherapy for alopecia areata

AU - Vázquez-Herrera, Norma Elizabeth

AU - Tosti, Antonella

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: Alopecia areata is a genetic and inflammatory disease that causes cosmetic and emotional distress. Current treatments are mainly focused in controlling inflammation, thus allowing hair regrowth, but not preventing relapse. Recent advances in the knowledge of the pathogenesis at the immunological and genetic level have provided new therapeutic approaches for this condition.Areas covered: Literature regarding available and future treatment options for alopecia areata was reviewed. We describe the mechanisms involved in its physiopathology and discuss extensively existing evidence for current treatment and status of new drugs, which act on specific target molecules such as Janus kinase (JAK) inhibitors, abatacept, IL-2, Hu-Mik-β-1, anti-IFN-γ, platelet-rich plasma (PRP), stem cell educator therapy, ezetimibe/simvastatin and tianeptine.Expert opinion: Advances in the knowledge of the physiopathology of alopecia areata have led to the discovery of new therapeutic targets for this illness. Treatments that have been successful in case reports or small studies are JAK inhibitors, abatacept, IL-2, anti-IFN-γ, PRP, ezetimibe/simvastatin and tianeptine. Even though these drugs have different mechanisms of action, their success will direct future research on drugs that act on a specific target. More clinical trials are needed to establish the safety and efficacy of these drugs, however, new treatment strategies are underway.

AB - Introduction: Alopecia areata is a genetic and inflammatory disease that causes cosmetic and emotional distress. Current treatments are mainly focused in controlling inflammation, thus allowing hair regrowth, but not preventing relapse. Recent advances in the knowledge of the pathogenesis at the immunological and genetic level have provided new therapeutic approaches for this condition.Areas covered: Literature regarding available and future treatment options for alopecia areata was reviewed. We describe the mechanisms involved in its physiopathology and discuss extensively existing evidence for current treatment and status of new drugs, which act on specific target molecules such as Janus kinase (JAK) inhibitors, abatacept, IL-2, Hu-Mik-β-1, anti-IFN-γ, platelet-rich plasma (PRP), stem cell educator therapy, ezetimibe/simvastatin and tianeptine.Expert opinion: Advances in the knowledge of the physiopathology of alopecia areata have led to the discovery of new therapeutic targets for this illness. Treatments that have been successful in case reports or small studies are JAK inhibitors, abatacept, IL-2, anti-IFN-γ, PRP, ezetimibe/simvastatin and tianeptine. Even though these drugs have different mechanisms of action, their success will direct future research on drugs that act on a specific target. More clinical trials are needed to establish the safety and efficacy of these drugs, however, new treatment strategies are underway.

KW - Abatacept

KW - Alopecia totalis

KW - Alopecia universalis

KW - IFN-γ inhibitors

KW - IL-2

KW - Janus kinase inhibitors

KW - Methotrexate

KW - Platelet-rich plasma

KW - Ruxolitinib

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84961354924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961354924&partnerID=8YFLogxK

U2 - 10.1517/21678707.2015.1021778

DO - 10.1517/21678707.2015.1021778

M3 - Article

AN - SCOPUS:84961354924

VL - 3

SP - 419

EP - 431

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 4

ER -